



## Deruxtecan [BSA] (DAG-WT672B)

This product is for research use only and is not intended for diagnostic use.

### PRODUCT INFORMATION

<b>Product Overview</b>	Deruxtecan conjugated with BSA
<b>Conjugate</b>	BSA
<b>Cas.No</b>	1599440-13-7
<b>Applications</b>	N/A
<b>Format</b>	Liquid
<b>Concentration</b>	Batch dependent - please inquire should you have specific requirements
<b>Size</b>	1 mg
<b>Buffer</b>	PBS buffer
<b>Preservative</b>	None
<b>Storage</b>	Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles

### BACKGROUND

<b>Introduction</b>	Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable peptide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conjugates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody–drug conjugate. DS-8201a significantly suppressed tumor growth in an immunocompetent mouse model with human HER2-expressing CT26.WT (CT26.WThER2) cells. DS-8201a is currently in clinical trials
<b>Keywords</b>	Deruxtecan; Trastuzumab deruxtecan; Glycinamide